Vir Biotechnology

Youtube Subscribe

Open: 25.97 Close: 25.43 Change: -0.54

Our AI found 6 flaws in Vir Biotechnology Company Inc Stock.

The game is changing. There is a new strategy to evaluate Vir Biotechnology fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vir Biotechnology are: Vir, Biotechnology, share, announces, multiple, abstract, highlight, …

Concept Map

Semantic Network

Stock Summary

Vir Biotechnology, Inc. develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat S.

Today's Summary

Vir Biotherapy stock was originally listed at a price of $14.02 in Oct 11, 2019. Phillip Pang, Chief Medical Officer, sold 5,000 shares in Vir Biotechnologys for $129,727.

Today's News

Vir Biotechnology announces multiple abstracts highlighting new hepatitis b and d data accepted for presentation at easl™ congress 2023. Vir Biotech is included in 1 Expert Collection, including Biopharma Tech. Vir Biotechnology shares are trading down 1.27% at $25.71 at the time of this writing on Wednesday morning. Phillip Pang, Chief Medical Officer, on June 07, 2023, sold 5,000 shares in Vir Biotechnologys for $129,727. Phillip has control over a total of 188,000 sha. Vir Biotechnology stock was originally listed at a price of $14.02 in Oct 11, 2019. If you had invested in Vir Biotechnologys stock at $14.02, your return over the last 3 years would have been 84.59%. Vir Biotechnology announces multiple abstracts highlighting new hepatitis b and d data accepted for presentation at easl™ congress 2023. Job application for manager, publications (temporary) at vir biotechnology. Vir Biotechnology is a commercial-stage immunology company, developing therapeutic products to treat and prevent serious infectious diseases. Morgan Stanley boosted their price target on shares of Vir Biotech from $25.00 to $27.00 in a report on Tuesday, April 4th. TheStreet lowered Vir Biotherapy from a “c” rating.

Stock Profile

"Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California."

Keywords

This document will help you to evaluate Vir Biotechnology without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vir Biotechnology are: Vir, Biotechnology, share, announces, multiple, abstract, highlight, and the most common words in the summary are: vir, biotechnology, stock, new, company, hepatitis, news, . One of the sentences in the summary was: Vir Biotherapy stock was originally listed at a price of $14.02 in Oct 11, 2019. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #vir #biotechnology #stock #new #company #hepatitis #news.

Read more →

Youtube Subscribe

---